Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4974727 | 1.00 | CYP3A4 (0.35) | CYP3A4TDP1MAOB | |
| SCHEMBL4974734 | 1.00 | CYP3A4 (0.35) | CYP3A4TDP1MAOB | |
| SCHEMBL4972429 | 0.84 | CYP3A4 (0.43) | CYP3A4TDP1MAOB | |
| SCHEMBL9861833 | 0.79 | CYP3A4 (0.32) | CYP3A4TDP1 | |
| SCHEMBL9861825 | 0.79 | CYP3A4 (0.32) | CYP3A4TDP1 | |
| SCHEMBL4974731 | 0.79 | ACHE (0.32) | TDP1 | |
| SCHEMBL25386183 | 0.77 | CYP3A4 (0.38) | CYP3A4TDP1 | |
| SCHEMBL15364455 | 0.76 | CYP3A4 (0.36) | CYP3A4TDP1MAOB | |
| SCHEMBL14819091 | 0.76 | CYP3A4 (0.36) | CYP3A4TDP1MAOB | |
| SCHEMBL14262345 | 0.76 | CYP3A4 (0.36) | CYP3A4TDP1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11355721-B2 | Organic light emitting device comprising polar matrix, metal dopant and silver cathode | NOVALED GMBH (DE) | 2022-06-07 | — | — | US | disclosed |
| US-20150034927-A1 | MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENT, AND ORGANIC ELECTROLUMINESCENT ELEMENT USING SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2015-02-05 | — | — | US | disclosed |
| US-20050288304-A1 | Tetrahydronaphthylpiperazines as 5HT1B antagonists, inverse agonists and partial agonists | PFIZER INC | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288304-A1 | Tetrahydronaphthylpiperazines as 5HT1B antagonists, inverse agonists and partial agonists | HTR1A, HTR1B, HTR1D | CYP3A4 1668/4885TDP1 2401/4885MAOB 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.